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Summary
Tribbles homolog 2 (Trib2) was identified as a downregulated transcript in leukemic cells undergoing growth arrest. To
investigate the effects of Trib2 in hematopoietic progenitors, mice were reconstituted with hematopoietic stem cells retro-
virally expressing Trib2. Trib2-transduced bone marrow cells exhibited a growth advantage ex vivo and readily established
factor-dependent cell lines. In vivo, Trib2-reconstituted mice uniformly developed fatal transplantable acute myelogenous
leukemia (AML). In mechanistic studies, we found that Trib2 associated with and inhibited C/EBPa. Furthermore, Trib2
expression was elevated in a subset of human AML patient samples. Together, our data identify Trib2 as an oncogene
that induces AML through a mechanism involving inactivation of C/EBPa.Introduction
Acute myelogenous leukemia (AML) is a genetically and pheno-
typically heterogeneous disease that is characterized by a block
in myeloid differentiation, as well as enhanced proliferation and
survival (Kelly and Gilliland, 2002). AML is frequently associated
with chromosomal translocations that target transcription fac-
tors such asmembers of the core binding factor (CBF) family, re-
sulting in fusion proteins that include AML1/ETO [t(8;21)], CBFb/
SMMHC [inv(16)], and TEL/AML1 [t(12;21)]. Mutations in tran-
scription factors such as PU.1, C/EBPa, AML1, and GATA-1
are also associated with AML, as are other types of oncogenic
perturbations that lead to functional inactivation of critical tran-
scription factors (Mueller and Pabst, 2006; Rosenbauer et al.,
2005; Tenen, 2003). Recurrent involvement of a limited set of
transcription factors suggests that disruption of these genes is
rate limiting for leukemia development.
Tribbles was first identified in Drosophila as a gene that is re-
quired for gastrulation, oogenesis, and viability (Grosshans and
Wieschaus, 2000; Mata et al., 2000; Seher and Leptin, 2000).CANCER CELL 10, 401–411, NOVEMBER 2006 ª2006 ELSEVIER INC. DTribbles coordinates cell division during gastrulation by promot-
ing turnover of the cell cycle protein String/CDC25, thereby
inhibiting premature mitosis. In this context, loss of Tribbles
function was associated with increased proliferation, whereas
overexpression of Tribbles slowed the cell cycle (Mata et al.,
2000). Tribbles also promotes the degradation of slbo, the
Drosophila homolog of the C/EBP family of basic region-leucine
zipper transcription factors, during oogenesis (Rorth et al.,
2000). Based on amino acid sequence, Tribbles resembles a
serine-threonine kinase; however, it has a variant catalytic core
that lacks a canonical ATP binding site, and how it functions is
unknown.
Mammals have three homologs of Tribbles—Trib1, Trib2, and
Trib3. During fasting conditions, Trib3 negatively regulates AKT
in the liver (Du et al., 2003) and binds the E3 ligase COP1 to de-
gradeACC in adipose tissue (Qi et al., 2006). It is also a transcrip-
tional target of the nuclear hormone receptor PPARa (Koo et al.,
2004). These findings are consistent with a function downstream
of the insulin receptor. Trib3 is also upregulated in tumor cells
and in hypoxic conditions (Bowers et al., 2003). Less is knownS I G N I F I C A N C E
AML, a heterogeneous disease characterized by increased proliferation and a block in differentiation, is commonly associated with
chromosomal translocations and transcription factor perturbations. We identified Trib2 as an oncogene that efficiently produces
AML in mice. Retroviral Trib2 expression in hematopoietic stem cells perturbed myeloid development, enhanced progenitor prolifera-
tion, and directly inhibited the function of C/EBPa, a critical transcription factor that is frequently dysregulated in AML. Trib2 expression
was upregulated in a subset of primary patient-derived AML samples, suggesting that it also contributes to the development of human
AML. The identification of Trib2 as a potent leukemogen points to alternative pathogenicmechanisms and possible therapeutic oppor-
tunities in this aggressive cancer, which is not currently curable in the majority of patients.OI 10.1016/j.ccr.2006.09.012 401
A R T I C L EFigure 1. Trib2 perturbs myeloid development in vivo and promotes self-renewal in vitro
B6 mice were lethally irradiated and reconstituted with BM cells transduced with control MigR1 vector or Trib2. Flow cytometric analysis of MigR1 and Trib2
chimeric mice at 9–14 weeks post-BMT.
A and B: BM (A) and spleen (B) showing GFP positivity and Gr-1hiCD11b+ neutrophils (percentages given) in the GFP+ and GFP2 fractions (left panel). In the
right panel, F4/80+CD11b+ monocytes (percentages given) in the GFP+ and GFP2 fractions are shown. Results are representative of three independent
experiments using six mice.
C: GFP+ BM cells (25,000) sorted from MigR1 and Trib2 chimeric mice at week 9 post-BMT were plated in methylcellulose in the presence of the indicated
cytokines. Colonies with >50 cells were scored after primary plating (9 days), secondary replating (15,000 cells, 10 days), tertiary replating (15,000 cells,
8 days), and growth in liquid culture (8 days) in triplicate. The mean numbers of colonies, 6SEM, for each condition are tabulated. ‘‘++’’ indicates colony
growth or growth in liquid culture.
D: Five thousand sorted GFP+, lin2 BM cells from Trib2 and MigR1 chimeras were plated in triplicate in methylcellulose containing IL-3, IL-6, SCF, and GM-CSF.
Single colonies from primary MigR1 and Trib2 plates at day 9 were replated in liquid culture plus cytokines (IL-3, IL-6, SCF) in 24-well plates and assessed for
growth after 11 days (growth = cell expansion and yellow media).
E: FACS analysis of MigR1 and Trib2 cells from a representative liquid culture in D.about the other two mammalian Trib family members. When
overexpressed, Trib1 can inhibit MEKK-1-mediated activation
of AP-1 and stress kinase signaling (Hegedus et al., 2006;
Kiss-Toth et al., 2004). Molecular data for Trib2, originally iden-
tified as a phosphoprotein in canine thyroid cells (Wilkin et al.,
1997), are limited to a study identifying it as a possible autoan-
tigen in autoimmune uveitis (Zhang et al., 2005) and as adifferen-
tially expressed gene in kidneymesenchymal cells and in a pros-
tate cancer cell line (Bisoffi et al., 2004; Takasato et al., 2004).
To investigate Trib2’s function in hematopoiesis, we retrovir-
ally expressed it in murine hematopoietic progenitors, which
were studied for changes in growth and differentiation in vivo
and in vitro. This led to long-term growth of myeloid progenitors
in vitro and induction of AML in vivo. Our biochemical studies
suggest that an important function of Trib2 in transformation is
to inactivate C/EBPa. Furthermore, an analysis of microarray
data generated from 285 AML patient samples identified ele-
vated Trib2 expression in a distinct subset of patients in a cluster
with a high frequency of C/EBPa mutations. Together, these402data identify Trib2 as a leukemogenic oncogene with the capac-
ity to dysregulate C/EBPa signaling.
Results
Trib2 perturbs myeloid development in vivo
We identified Trib2 as a transcript that was downregulated after
treatment of Notch-dependent murine T-ALL cell lines with g
secretase inhibitors (unpublished data). As little was known
about Trib2 function, we initiated studies to determine its effects
on hematopoiesis. Lethally irradiated C57BL/6 (B6) mice were
reconstituted with Trib2 or retroviral control vector (MigR1)-
transduced hematopoietic progenitors as described (Pui et al.,
1999). At 9–14 weeks post-bone marrow transplant (BMT),
MigR1 and Trib2 chimeric mice were similar in terms of bone
marrow (BM) and splenic cellularity, the overall percentage of
GFP+ cells, and the peripheral white blood cell (WBC) counts
(Figures 1A and 1B, left panels). However, granulocytes
(CD11b+Gr-1hi) were reduced in the GFP+ BM population ofCANCER CELL NOVEMBER 2006
A R T I C L EFigure 2. Trib2 induces AML
A: Kaplan-Meier survival curve of mice receiving Trib2-transduced BM compared to MigR1 control. The median survival of Trib2 mice was 179 days. Results are
derived from seven independent experiments.
B: Representative photographs of splenomegaly in Trib2 mice compared to control MigR1 spleen, and lymphadenopathy in Trib2 mice.
C: Wright-Giemsa-stained PB and BM single cell suspensions from MigR1 and leukemic Trib2 mice. Scale bars (upper right) represent 10 mm. The percentage of
GFP+ cells in Trib2 BM was approximately 90%–100%.
D: Histopathology of BM sections from Trib2-induced AML. Hematoxylin and eosin (H+E) section showing hypercellularity (top left) due to the presence of
sheets of immature cells and blasts (top right). The tumor cells stain positively for myeloperoxidase (MPO, bottom left) and negatively for terminal deoxytrans-
ferase (TdT, bottom right). Scale bars (lower right) represent 20 mm.Trib2 chimeric mice (Figures 1A and 1B, center panels), and
monocytes (CD11b+F4/80+) were significantly increased in the
GFP+ population of both the BM and spleen of Trib2 mice (Fig-
ures 1A and 1B, right panels), suggesting that enforced expres-
sion of Trib2 promotes monocytic differentiation and inhibits
granulocytic differentiation. Further characterization of myeloid
subsets showed the presence of increased numbers of
CD11b+CD11c+MHCII+ dendritic cells (DCs) and CD11b+F4/
80+MHCII+macrophages in theGFP+ population of Trib2 chime-
ric mice as compared to MigR1 control mice (Figures S1A and
S1B in the Supplemental Data available with this article online).
In contrast to myeloid development, Trib2-GFP+ lymphoid cells
obtained from the BM, lymph nodes, and thymus did not reveal
developmental abnormalities (data not shown). These experi-
ments suggest that enforced Trib2 expression perturbed mye-
loid development.
Trib2-transduced progenitors exhibit a growth
advantage in vitro and establish long-term
myeloid progenitor cell lines
To assay the proliferative potential of Trib2-transduced cells
in vitro, sorted GFP+ cells from the BM of MigR1 and Trib2 chi-
meras at 9–10 weeks post-BMT were plated in methylcellulose
in the presence of IL-3 or GM-CSF. Significant differences in col-
ony numbers were observed in both IL-3 and GM-CSF (Fig-
ure 1C). When replated, Trib2 cells formed secondary coloniesCANCER CELL NOVEMBER 2006in both IL-3 and GM-CSF, whereas MigR1 primary colonies
did not. Cells from Trib2 secondary colonies formed tertiary
colonies, and cells transferred from these colonies to liquid
culture exhibited factor-dependent (IL-3 and GM-CSF) long-
term growth (Figure 1C). Lineage-depleted GFP+ BM progenitor
cells sorted from MigR1 and Trib2 chimeras were then assayed
for proliferation. Single colonies were randomly picked from
primary methylcellulose plates and replated in liquid media
containing IL-3, IL-6, and SCF. Cells from MigR1 colonies did
not proliferate in liquid medium, whereas cells from 46/48
Trib2 colonies exhibited factor-dependent long-term growth in
liquid cultures (Figure 1D). These Trib2-expressing cell lines
remained factor dependent and did not produce leukemia
when injected into recipient mice (data not shown). The prolifer-
ating Trib2 cells did not express lineage markers (Gr-1, Ter119,
CD3, CD8, CD4, B220, CD19, CD11c, CD11b) or Sca-1 but did
express c-Kit and CD16/32 (FcgIII/II) as compared to MigR1
control cells (Figure 1E). These data suggest that Trib2 expres-
sion in myeloid progenitors promotes replating and self-renewal
activities.
Mice reconstituted with Trib2 bone marrow
cells develop AML
Trib2 chimeric mice died prematurely at a median of 179 days
post-BMT (Figure 2A and Table S1, one outlier mouse of n =
26). These data include mice from multiple independent BMT403
A R T I C L EFigure 3. Analysis of Trib2-induced AML
A: Flow cytometric analysis of GFP expression (percentages given), forward scatter (FSC), and side scatter (SSC) in cells obtained from BM and spleens of
leukemic mice. Mean fluorescence intensities (MFI) of FSC of the GFP+ cells are shown 6 SD.
B and C: Immunophenotypes of primary Trib2-induced AML cells from lymph nodes (LN), thymus, spleen, and BM compared to control MigR1 cells. Flow
cytometric analysis of Gr-1 and CD11b expression (B) and c-Kit and F4/80 expression (C), in the GFP+ fraction of MigR1 (top) and Trib2 (bottom panels)
mice. The percentages of cells that are Gr-12CD11b2 are shown in B, and the percentages of cells that are c-Kit2F4/802 are shown in C. Results are repre-
sentative of seven independent experiments.
D: Schematic of Trib2 provirus and probe used for Southern blotting.
E and F: Southern blot detection of proviruses in Trib2 mice. DNA preparations were digested with either Xba1 to detect intact provirus (w4 kb) (E) or BglII or
EcoR1, which cleaved once in the provirus, to detect different proviral integrants (F). All leukemic samples were obtained from different primary mice; lanes 1
and 7 contain control DNAs from B6 mouse spleen (Spl) and MigR1 control spleen, respectively.
G: Real-time RT-PCR analysis of Trib2 expression in cDNAs from six primary Trib2-induced AML tumor spleen samples (1–6), using murine Trib2-specific primers. The
results are presented as Trib2 mRNA in AML samples relative to expression in control MigR1 spleen cells (Ctrl1, Ctrl2), normalized for 18S rRNA content. Error bars
denote 6SD of each sample measured in triplicate.
H: Analysis of Trib2 protein expression by western blot. Extracts of primary Trib2-induced AML cells obtained from spleen (>90% GFP, MigR1-Trib2-FLAG) were
compared to extracts prepared from control MigR1 spleen cells and 293T cells transfected with pcDNA-Trib2-FLAG. Trib2-FLAG polypeptides were detected
on the blot with the FLAG antibody (M2, Sigma). ns, nonspecific band.experiments performed with different Trib2 retroviral constructs
(MigR1-Trib2, MigR1-Trib2-Flag-tagged, tNGFR-Trib2-Flag-
tagged). The peripheral blood (PB) prior to death exhibited a leu-
kocytosis consisting of blasts and immature myelomonocytic
cells (Figure 2C and Table S1). At necropsy, all mice displayed
splenomegaly and lymphadenopathy (Figure 2B and Table
S1). Morphologically, the infiltrating cells in these tissues resem-
bled those seen in the PB; mature granulocytes were notably
absent (Figure 2C). Histologic sections revealed extensive
(>80% in all cases) involvement of the BM by myeloblasts and
immature myelomonocytic cells (Figure 2D, top panels). Blasts
made up >20% of the BM cellularity in all affected animals, sup-
porting the diagnosis of AML. Leukemic cells found in the
spleen, liver, lymph nodes, and blood had similar morphologic404and immunophenotypic characteristics (data not shown). By im-
munohistochemical staining, these cells were positive for mye-
loperoxidase (a marker of myeloblasts and more mature granu-
locytes) and were negative for terminal deoxytransferase (a
marker of lymphoblasts) (Figure 2D, lower panels). Cytochemi-
cal stains for nonspecific esterase, a marker of monocytes,
were negative (data not shown).
Flow cytometric analysis revealed that the leukemic cells were
GFP+ and relatively large in size (as judged by forward scatter,
Figure 3A) and expressed intermediate levels of Gr-1 and
CD11b (Figure 3B), as well as c-Kit and F4/80 (Figure 3C). The
coexpression of Gr-1 and CD11b at low/intermediate levels is
characteristic of immature myeloid precursors and murine mye-
loid leukemias (Cozzio et al., 2003; de Guzman et al., 2002).CANCER CELL NOVEMBER 2006
A R T I C L EThe overall combination of morphologic and immunophenotypic
findings is consistent with AML.
To detect provirus, DNA was isolated from the lymph nodes
and spleens of chimeric mice and analyzed by digestion with
restriction endonucleases (Figure 3D). These studies revealed
that all tumors contained intact provirus (Figure 3E) and that
individual tumors contained one to several distinct proviral
insertions (Figure 3F). The intensity of the bands indicated that
the tumors were either monoclonal (Figure 3F, lanes 2, 3, and
4) or biclonal (Figure 3F, lanes 5 and 6), suggesting that addi-
tional genetic events are necessary to generate Trib2-induced
AML. In addition to GFP (Figure 3A), the tumor cells expressed
both Trib2 mRNA (Figure 3G) and protein (38 kDa, Figure 3H).
Because antibodies against Trib2 are not available, the latter
was detected in a cohort of tumors inducedwith epitope-tagged
Trib2 retrovirus.
To further establish the malignancy of Trib2 leukemia, cells
(2 3 106) from the BM and spleens of primary leukemic mice
were transplanted into sublethally irradiated secondary recipi-
ents. All secondary recipients developed AML with an average
latency of 36 days (Figure 4A and Table S2). Secondary leuke-
mias were associated with leukocytosis and extensive involve-
ment of the BM, liver, spleen, and other tissues (Figure 4B and
Table S2). The immunophenotype of the leukemic cells in sec-
ondary recipients resembled that of the primary disease, with
most cells retaining intermediate expression of Gr-1 and CD11b
(Figure 4B) and expression of F4/80 (Figure 4C). In addition, the
leukemic cells were c-Kit+, Sca-12, CD34intermediate, and CD16/
32+ (FcgIII/II) (Figure 4D). Together, these data indicate that
Trib2 is a potent leukemogen.
Trib2 reduces normal C/EBPa levels and inhibits
C/EBPa function
A deficiency of the transcription factor C/EBPa inhibits granulo-
cyte differentiation and is associated with AML (Tenen, 2003),
features similar to the consequences of Trib2 expression in he-
matopoietic progenitors. Furthermore, Drosophila Tribbles can
promote the degradation of Slbo, the Drosophila homolog of
C/EBP, during oocyte border cell migration (Rorth et al., 2000).
To determine whether Trib2 alters C/EBPa protein levels in my-
eloid cells, western blot analysis was performed on whole-cell
extracts prepared from 32D and U937 cells transduced with
MigR1 or Trib2. In both cell lines, Trib2 expression reduced
levels of the C/EBPap42 full-length protein and concomitantly
increased levels of C/EBPap30 (Figure 5A), a dominant-negative
variant of C/EBPap42 that is thought to arise from an internal
translation initiation site (Calkhoven et al., 2000).
Human AML is associated with mutations in C/EBPa that lead
to decreased levels of normal C/EBPap42 and increased levels
of C/EBPap30 (Leroy et al., 2005; Pabst et al., 2001b).
C/EBPap30 dominantly inhibits C/EBPap42 function when the
ratio of C/EBPap42 to C/EBPap30 is less than one (Calkhoven
et al., 2000). In contrast to normal CMPs and GMPs (Akashi
et al., 2000), high levels of C/EBPap30 and low ratios of C/
EBPap42 to C/EBPap30 were present in all Trib2 primary leuke-
mic samples (Figure 5B, left panel). The inverted ratio of C/
EBPap42 to C/EBPap30 protein persisted in serially passaged
leukemic cells (Figure 5B, right panel). The identity of C/
EBPap30 was confirmed by performing additional western blots
with an antibody specific for the N-terminal C/EBPa epitope,
which detected only C/EBPap42 (data not shown).CANCER CELL NOVEMBER 2006To show that the relative decrease in C/EBPap42 translated
into diminished functional activity, we investigated whether
Trib2 inhibited activation of an IL-12 promoter luciferase reporter
by C/EBPa. This reporter contains a single C/EBPa binding site,
which is involved in the induction of IL-12 transcription in RAW
cells following LPSexposure (Figure 5C). Trib2 inhibited the stim-
ulation of an IL-12 reporter construct by both C/EBPap42 and
LPS (Figure 5D). In both experiments, the stimulation of reporter
gene activity by C/EBPa or LPS required an intact C/EBPa bind-
ing site (Figure 5D). Trib2 had no effect on an NFkB-sensitive lu-
ciferase reporter gene (Figure S2A), suggesting that the effect of
Trib2 was specific for C/EBPa. Furthermore, the IL-6 promoter
also contains a functional C/EBPa binding site, and BM-DCs
and macrophages derived from Trib2 chimeric mice released
less IL-12 and IL-6 in response to LPS than did MigR1 control
cells (Figures S2B–S2E). To further characterize the relationship
between C/EBPa and Trib2, the C/EBPa DNA binding activity
was assayed in extracts prepared from transduced U937 cells.
The C/EBPa-DNA binding activity was markedly reduced by
Trib2 (Figure 5E, lanes 1 and 3), with the specificity of the ob-
served gel shift being confirmed by production of a ‘‘supershift’’
upon addition of an antibody against C/EBPa (Figure 5E, lane 2
Figure 4. Trib2-induced AML is 100% transplantable
A: Kaplan-Meier survival curve of secondary transplants. Sublethally irradi-
ated mice (600 rads) received 2 3 106 BM or spleen cells from eight primary
leukemic mice.
B–D: Immunophenotype of Trib2-induced AML after secondary transplant.
Cells from BM, spleen, and PB were assessed by flow cytometry. B: The
Gr-1 and CD11b profile of the GFP+ population is shown; percentages given
are cells negative for both markers. C: F4/80 profile of the GFP+ Trib2 cells
(black line) are overlaid on the normal F4/80 staining profile of B6 control
BM cells (gray line). Results shown are representative of n = 8 mice. D: The
c-Kit and isotype/Sca-1/CD34/CD16/32 profile of the GFP+ population is
shown.405
A R T I C L EFigure 5. Trib2 reduces normal levels of C/EBPa
and inhibits its activity
A: Sorted GFP+ 32D and U937 cells transduced
with either MigR1 or Trib2 were assessed
for C/EBPa protein expression by western blot.
C/EBPap42 is the full-length protein, and
C/EBPap30 is the truncated protein. Actin is the
protein loading control.
B: Analysis of C/EBPap42 and p30 protein expres-
sion in primary leukemic samples from BM (93%
GFP+), spleen (63% GFP+), and lymph node
(88% GFP+) compared to normal levels ex-
pressed in CMPs and GMPs from B6 BM (left
panel). Levels of C/EBPap42 and p30 proteins
were also compared in unfractionated normal
B6 mouse BM cells and primary (94% GFP+) and
secondary (98% GFP+) leukemic BM samples
(right panel).
C: Schematic of the IL-12 promoter containing
the C/EBPa binding site.
D: RAW264.7 macrophages were cotransfected
with (1) the IL-12 promoter firefly luciferase con-
structs containing the C/EBP wild-type or mutant
binding sites; (2) either empty vector, Trib2,
C/EBPa, or both Trib2 and C/EBPa; and (3) a
pRL-TK Renilla luciferase internal control plasmid.
Luciferase activity was measured following LPS
(100 ng/ml) treatment for 8 hr, 24 hr posttransfec-
tion. Reporter luciferase activity for each sample
was normalized to the Renilla luciferase activity
of the same sample. Data presented are
mean 6 SD of triplicate cultures.
E: C/EBPa DNA binding activity was assessed by
EMSA using a double-stranded oligonucleotide
probe containing the C/EBP binding site from the human G-CSF receptor. Nuclear extracts from sorted GFP+ U937 cells transduced with MigR1 (lanes 1
and 2), Trib2 (lanes 3 and 4), or C/EBPa (lanes 5 and 6) were incubated with 32P-labeled probe. In lanes 2, 4, and 6, 2 ml of C/EBPa antibody was added.
‘‘SS’’ indicates the supershifted C/EBPa complex. The extracts used in lanes 1, 3, and 5 were tested with an OCT-1 probe in a second EMSA assay as a control
for the integrity and quantity of nuclear binding proteins.and4). Thesedata demonstrate that Trib2 expression inhibits the
DNA binding function of C/EBPap42.
As Trib2 overexpression decreased C/EBPap42, we investi-
gated whether siRNA-mediated knockdown of endogenous
Trib2 would increase endogenous C/EBPap42. Indeed, human
U937 cells transfected with siRNA against human Trib2 had re-
duced Trib2 mRNA expression (Figure 6A) and a concomitant
increase in C/EBPap42 protein (Figure 6B). C/EBPap30 is not
detectable in these cells (see Figure 6D). Moreover, siRNA-
mediated knockdown of retrovirally expressed murine Trib2 in
U937 cells reduced murine Trib2 expression (Figure 6C) and
abrogated its inhibitory effect on C/EBPap42 (Figure 6D). Trib2
knockdown restored the C/BPap42:C/EBPap30 ratio by in-
creasing C/EBPap42 expression. The failure to observe a
concomitant decrease in C/EBPap30 may stem from a long
C/EBPap30 half-life, residual Trib2 activity, or other unknown
factors, and is a point that requires further investigation. Never-
theless, these data complement the Trib2 overexpression
studies and further support the hypothesis that Trib2 opposes
C/EBPap42 function.
To further investigate the link between Trib2’s inhibitory ef-
fects on granulopoiesis (Figure 1A) and C/EBPap42 activity,
we coexpressed Trib2 and C/EBPap42 in 32D cells, which re-
quire IL-3 to survive and undergo C/EBPap42-dependent gran-
ulocytic differentiation in response to G-CSF (Wang et al., 1999).
To control C/EBPap42 activity, we utilized an estradiol-inducible
C/EBPap42 fusion gene (C/EBPaER) cloned in MigR1 (Cam-
menga et al., 2003). In these experiments, Trib2 was expressed406in a MSCV retrovirus that also bears a tNGFR gene as a surro-
gate marker (Izon et al., 2001). 32D cells were sorted for retrovi-
ral expression of GFP (C/EBPaER), tNGFR (Trib2), or both,
treated with either estradiol or vehicle in the presence of either
IL-3 or G-CSF, and then assayed for granulocytic differentiation
by both flow cytometry (Figure 6E) and morphology (data not
shown). As expected, vehicle-treated cells transduced with C/
EBPaER differentiated only in the presence of G-CSF (induction
of endogenous C/EBPa activity), whereas estradiol (induction of
exogenous C/EBPa activity) induced the differentiation of these
cells in the presence of either G-CSF or IL-3 (Figure 6E). Further,
cells transduced with Trib2 failed to differentiate in response to
either G-CSF or IL-3, as did cells that were cotransduced with
Trib2 and C/EBPaER in the presence of vehicle. In contrast,
the inhibitory effect of Trib2 in doubly transduced cells was
overcome by estradiol treatment, indicating that high doses of
C/EBPa overcome the inhibitory effects of Trib2.
Cell proliferation and survival were also assayed in these cul-
tures by cell counting and trypan blue exclusion. 32D-C/
EBPaER cells proliferated in IL-3, and this proliferation was in-
hibited by either endogenous or exogenous C/EBPa activity
(Figure S3, left bars). 32D-Trib2 cells proliferated in the presence
of IL-3 but died in the presence of G-CSF (Figure S3, middle
bars), an effect that was similar to transduction of 32D cells
with a C/EBPa DNA binding mutant that was unable to induce
differentiation (Keeshan et al., 2003). Cell numbers/viability
were restored following estradiol induction of C/EBPa in the
Trib2 + C/EBPaER-expressing cells (Figure S3, compare twoCANCER CELL NOVEMBER 2006
A R T I C L EFigure 6. Trib2-dependent inhibition of C/EBPa
expression and function is abrogated by siRNA-
mediated knockdown of Trib2 and overexpres-
sion of C/EBPa
A and B: siRNA designed to knock down human
Trib2 (hTrib2) was electroporated into U937 cells
and analyzed 24 hr later. A: hTrib2 expression as-
sessed by real-time RT-PCR. Error bars denote
6SEM of each sample measured in triplicate. B:
Western blot of C/EBPa protein expression. Lane
1, negative control siRNA; lane 2, hTrib2 siRNA.
C/EBPap30 is undetectable in parental U937
cells.
C and D: siRNA designed to knock down murine
Trib2 (mTrib2) was electroporated into U937 cells
retrovirally expressing murine Trib2 and analyzed
24 hr later. C: mTrib2 expression assessed by real-
time RT-PCR. Error bars denote 6SEM of each
sample measured in triplicate. D: Western blot
of C/EBPap42 and C/EBPap30 protein expres-
sion. Lanes 1 and 2, U937 cells + human Trib2
siRNA and negative control siRNA, respectively,
as in B; lanes 3 and 4, U937-mTrib2 cells + nega-
tive control siRNA and siRNA mTrib2, respectively.
ns, nonspecific band.
E: 32D cells transduced with C/EBPaER (GFP),
Trib2 (tNGFR), or C/EBPaER + Trib2 were sorted
for GFP and/or tNGFR expression. Sorted cells
were plated in equal numbers (1 3 105) (day 0,
48 hr posttransduction) in IL-3 or G-CSF 6 1 mM
b-estradiol (EST). CD11b expression was assessed
after 2 days. Data are representative of three
independent experiments.far right bars). Similar to the CD11b expression data, these
results also show that high doses of C/EBPa overcome Trib2’s
inhibitory effects.
We next sought to determine the mechanism by which Trib2
decreased normal C/EBPap42 levels. In 32D and U937 cells,
C/EBPap42 levels in Trib2-expressing cells were restored by
pretreatment with the proteasome inhibitor MG132 (Figure 7A).
In coimmunoprecipitation experiments using 293T cells, Trib2
association with C/EBPap42 was detected only in the presence
of MG132, whereas C/EBPap30 coimmunoprecipitated in the
presence and absence of MG132 (Figure 7B, lane 4 and 5).CANCER CELL NOVEMBER 2006Expression of Trib2 in U937 cells decreased the half-life of en-
dogenous C/EBPa protein as determined by 35S metabolic
pulse labeling and immunoprecipitation chase of labeled C/
EBPa (Figure 7C). These data suggest that Trib2 acts by associ-
ating with C/EBPap42 and promoting its degradation via the
proteasome.
Elevated Trib2 expression is found in a subset of AML
patients exhibiting C/EBPa defects
Since Trib2 is a potent inducer of AML in our experimental
model, we investigated Trib2 expression in a mRNA expressionFigure 7. Trib2 forms a complex with C/EBPa
and results in its proteasomal-dependent degra-
dation
A: Sorted GFP+ U937 (top panel) and 32D (lower
panel) cells transduced with either MigR1 or
Trib2, treated 6 10 mM MG132 for 2 hr, were as-
sessed for C/EBPa expression by western blot.
B: 293T cells were transfected with empty vector
(lane 1), myc-tagged Trib2 (lane 2), and HA-
tagged C/EBPa (lane 3), or cotransfected with
both (lanes 4 and 5), and treated with 10 mM
MG132 for 2 hr (lane 4). Trib2 was immunoprecip-
itated using a Myc 9E10 antibody, and western
blotting was performed with HA and Myc anti-
bodies on immunoprecipitates (top panel) and
total lysates (lower panel).
C: U937 cells transduced with MigR1 or Trib2 were
metabolically labeled with 35S-methionine for 60
min and chased for the indicated times. C/EBPa
was immunoprecipitated, and radiolabeled
protein was detected by SDS-PAGE. The half-
life (T1/2) was calculated using ImageJ software.407
A R T I C L Edatabase derived from 285 AML patient samples. Previous anal-
ysis of gene expression in this data set identified 16 groups of
AML with distinct gene expression profiles (Valk et al., 2004).
Based on signals from two different Trib2 probe sets, we noted
that elevated Trib2 expression was observed in cluster #4 (Fig-
ure 8), which is one of two clusters that are associated with C/
EBPa mutations (Valk et al., 2004). Although cluster 4 contains
AML samples with wild-type (green) or mutated (red) C/EBPa,
Trib2 expression was primarily elevated in tumors with wild-
type C/EBPa (Figure 8, enlarged area). Thus, in an unbiased
screen of AML samples, high levels of Trib2 expression were
preferentially found in a cohort associated withC/EBPa defects.
This association again links Trib2 to tumors with altered C/EBPa
function and suggests that elevated Trib2 may have a patho-
genic role in a subset of human AML.
Discussion
Our data provide strong evidence that dysregulated Trib2
expression contributes to the pathogenesis of AML. Retroviral
expression of Trib2 immortalized hematopoietic progenitors
in vitro and induced fatal transplantable AMLs in murine recipi-
ents with a mean latency of 179 days. In accordance with the
central role of Trib2 in the development of these tumors, we
have never observed AML in several hundred mice that have re-
ceived MigR1-transduced BM cells using identical protocols.
Microarray analysis of a cohort of primary human AMLs identi-
fied elevated Trib2 mRNA expression in a cluster of tumors as-
sociated with a high frequency of C/EBPa mutations. Although
we have not yet determined the mechanism of Trib2 upregula-
tion in these leukemias, our data linking Trib2 expression to in-
hibition of C/EBPa function suggests that Trib2 overexpression
is likely to be an important pathogenic mechanism in a subset of
human AML.
Decreased C/EBPap42 levels are observed in diverse molec-
ular subtypes of human AML (Helbling et al., 2004, 2005; Pabst
et al., 2001a; Perrotti et al., 2002; Westendorf et al., 1998) and
are sometimes associated with point mutations in C/EBPa
(Pabst et al., 2001b). A number of observations suggest that
Trib2-mediated alterations of C/EBPa function are likely to con-
tribute to AML induction. We found that Trib2 forms a complex
with C/EBPap42 that results in its destabilization through pro-
teasome-dependent degradation. We further demonstrated an
inverse functional relationship between Trib2 and C/EBPa
through both gain- and loss-of-function approaches. The effects
of C/EBPa on myeloid cell differentiation are opposed by en-
forced Trib2 expression, and we found high Trib2 expression
in a specific subset of human AMLs that is associated with
C/EBPamutations.We hypothesize that Trib2-expressing AMLs
lackingC/EBPamutations share a similar expression profile due
to functional inactivation of C/EBPa. It is unlikely, however, that
Trib2 causes AML only through C/EBPa inactivation. Mice bear-
ing knockout and mutated C/EBPa alleles have abnormalities of
myeloid differentiation but do not develop AML (Heath et al.,
2004; Zhang et al., 1997, 2004). Furthermore, despite its effect
on C/EBPa function, Trib2 is not sufficient for AML, as the
tumors arising in Trib2 mice were either mono- or biclonal.
In addition to C/EBPa, Trib2 may influence other signaling
pathways. In Drosophila, Tribbles degrades String/CDC25 to in-
hibit the cell cycle. Although it seems counterintuitive that de-
creased String/CDC25 would be oncogenic, antagonism of408String by Tribbles is associated with enhanced proliferation in
certain contexts in the fly (Mata et al., 2000). Other Trib family
members have been associated with Akt and MAPK signaling
(Hegedus et al., 2006), and it remains to be determined whether
Trib2 influences these pathways in AML cells.
It is also possible that proviral integration by the Trib2-
expressing retroviral vector created lesions in genes that co-
operate with Trib.We have begun to address this by cloning pro-
viral integrations in Trib2 tumors. In at least one Trib2 AML, the
provirus was found adjacent to HoxA9, whosemRNAwasmark-
edly elevated in this tumor (K.K., unpublished data). HoxA9 has
been shown to synergize with other oncogenes to accelerate
AML development (Kawagoe and Grosveld, 2005). We are cur-
rently investigating the functional significance of this finding.
An additional property of Trib2 is its association with in-
creased C/EBPap30 levels in cell lines and leukemic samples.
C/EBPa is an intronless gene, and it has been suggested that
the two major C/EBPa isoforms stem from alternative transla-
tional start sites. Other possibilities exist, however, as the
homologous protein C/EBPb is proteolytically processed into
full-length and N-terminally truncated dominant-negative iso-
forms (Baer and Johnson, 2000; Lin et al., 1993; Ossipow
et al., 1993; Welm et al., 1999). In our coimmunoprecipitation
experiments, the C/EBPa expression construct lacked the
uORF (upstream open reading frame) and contained a C-termi-
nal HA tag that was detected with a HA antibody and verified
with a specific C/EBPa antibody. This suggests that the
30 kDa protein is an N-terminal truncation of the full-length C/
EBPa induced by Trib2 expression. However, this construct re-
tains the alternative ATG start codon, and therefore translational
control cannot be ruled out. In favor of this possibility, we were
unable to detect C/EBPap30 in the pulse-chase experiment.
Although Trib2 potently induced AML in our BMT model, it is
not clear whether the diminution of C/EBPap42, the enhance-
ment of C/EBPap30, or both were critical to the phenotypes
that we observed. Decreased C/EBPap42 levels are associated
Figure 8. Trib2 is elevated in a subset of human AML
Correlation view of 285 AML patients (Valk et al., 2004). Colors of cells relate
to Pearson’s correlation coefficient values: red indicates higher positive and
blue indicates higher negative correlation between samples. Sixteen
clusters represented by red blocks along the diagonal can be identified.
C/EBPamutation status is indicated next to each tumor (red, mutant; green,
wild-type). Histograms next to each tumor represent expression levels of the
two probe sets for Trib2. Cluster 4, one of the two clusters harboring most
patients with C/EBPa mutations, has a significantly elevated expression of
Trib2 relative to other clusters.CANCER CELL NOVEMBER 2006
A R T I C L Ewith human AML (Mueller and Pabst, 2006), and mice engi-
neered to express a C/EBPap42 mutant that fails to block the
cell cycle develop a transplantable myeloproliferative disease
that progresses to an AML-like phenotype but does not affect
survival (Porse et al., 2005). Murine BM cells transduced with
the dominant-negative C/EBPap30 showed poor long-term en-
graftment (Schwieger et al., 2004). However, in CFU assays, the
C/EBPap30 dominant-negative was shown to block murine and
human myeloid differentiation (Iwama et al., 2002; Schwieger
et al., 2004; Wang and Friedman, 2002). Thus, both decreased
C/EBPap42 and increased C/EBPap30 have been associated
with myeloid transformation. Additional studies will be required
to determine which of these isoforms is most relevant to Trib2-
induced AML.
We initially identified Trib2 by screening for transcripts that
were downregulated when Notch1-dependent T cell tumor cell
lines were induced to growth arrest by g secretase inhibitor
treatment (Weng et al., 2003). Although we find that Trib2 ex-
pression is modulated by Notch1 via CSL binding sites in the
Trib2 promoter (unpublished data), mice that retrovirally express
activated Notch1 do not develop AML or exhibit major defects in
granulocyte differentiation. Trib2 regulation by Notch1 may be
context dependent and nonoperational in myeloid progenitors.
However, Notch signaling promotes macrophage/DC differenti-
ation in some assays (Cheng et al., 2003; Ohishi et al., 2001), and
it will be interesting to determine if this is Trib2 dependent. In ad-
dition, the subset of human AMLs associated with increased
Trib2 expression are very immature and express T cell markers,
such as TCRd (Valk et al., 2004). Trib2 is highly expressed during
several stages of T cell development (data not shown), and it is
possible that Trib2 normally contributes to the expression of
genes associated with T cell development.
Our data predict that Trib2 would functionally inactivate C/
EBPa by causing its degradation. Thus, one expectation would
be that it would associate with tumors in which C/EBPa is inac-
tivated. Analysis of microarray data obtained from 285 AMLs
showed that elevated Trib2 expression preferentially associated
with a cluster of AMLs characterized by C/EBPa defects. High
Trib2 expression was predominantly seen in tumors without C/
EBPa mutations; however, it was also high in two tumors with
thesemutations (Figure 8). It may be that induction of thismolec-
ular class of AML requires C/EBPa function to be suppressed
below a certain threshold, and that this may occur by mutation
alone, Trib2 expression, or a combination of these two factors.
In summary, our studies identify Trib2 as an oncoprotein that
contributes to the pathogenesis of AML through the inhibition of
C/EBPa function. This occurs through the interaction of Trib2
with C/EBPa, resulting in the proteasomal-dependent degrada-
tion of C/EBPa. Our observations suggest that multiple leuke-
mogenicmechanisms target C/EBPa in AML.Understanding the
precise role of Trib2 in AML may lead to new diagnostic and
therapeutic strategies for this aggressive human malignancy.
Experimental procedures
Constructs and retroviruses
A 1032 bp fragment encoding the entire murine Trib2 cDNA was subcloned
(6N terminus FLAG tag) into pcDNA3.1, pcDNA3.1/myc-HIS plasmid, or one
of two different versions of MigR1 (one coexpressing GFP, the other trun-
cated human nerve growth factor receptor [tNGFR]). C/EBPa rat cDNA (Kee-
shan et al., 2003) was cloned into the pcDNA3.1/myc-HIS plasmid. The
MigR1-C/EBPaER construct was a kind gift of Dr. S. Nimer. The IL-12 p40CANCER CELL NOVEMBER 2006promoter containing the B6 genomic fragment 2700 to +54 of the IL-12
p40 gene was cloned into the pGL3-basic vector (Promega), and site-di-
rected mutagenesis of the C/EBP binding site (293 to 289) was performed
using the QuickChange kit (Stratagene) according to the manufacturer’s in-
structions (kind gifts from Dr. R Carmody).
32D differentiation assay
32D cells were transduced with C/EBPaER (GFP), Trib2 (tNGFR + FLAG), or
both, sorted for GFP and/or tNGFR 48 hr posttransduction, and cultured
in DMEM without phenol red (GIBCO) containing 10% charcoal stripped
FCS (Gemini Bioproducts) and 5 ng/ml rIL-3. Cells (1 3 105) were plated in
5 ng/ml IL-3 or 25 ng/ml G-CSF 6 1 mM b-estradiol (Sigma, E2257) and as-
sessed for granulocytic differentiation by FACS analysis and morphological
criteria.
Methylcellulose clonogenic assays
Sorted GFP+ and GFP+/Lin2 (CD3, CD4, CD8, B220, Gr-1, Ter119, CD19,
MHCII, IL-7Ra) BM cells from MigR1 and Trib2 transplanted mice were
plated in triplicate in methylcellulose media (Methocult M3231, Stem Cell
Technologies) supplemented with cytokines (10 ng/ml GM-CSF, 10 ng/ml
IL-3, 10 ng/ml IL-6, 50 ng/ml SCF [Peprotech and BD Pharmingen]). Cells
(15,000) from primary plates (colonies scored at 9 days) were transferred
to secondary (colonies scored at 10 days) and tertiary (colonies scored at
8 days) plates containing the indicated cytokines, then transferred to RPMI
liquid culture supplemented with 10% FBS and cytokines. Single colonies
were transferred from primary plates to media containing IL-3, IL-6, and
SCF in 24-well plates and assessed for growth after 11 days.
Bone marrow transduction and transplantation
C57BL/6 mice (B6) were obtained from Taconic Farms. Experiments were
performed according to guidelines from the National Institutes of Health
and with an approved protocol from the University of Pennsylvania Animal
Care and Use Committee. Retroviral transduction of B6 BM cells and subse-
quent transfer of these cells into lethally irradiated recipients were performed
as described (Pui et al., 1999), and details are provided in the Supplemental
Experimental Procedures. Seven independent transplant experiments were
performed with different Trib2 retroviral constructs (MigR1-Trib2, MigR1-
FLAG-Trib2, NGFR-FLAG-Trib2); each gave similar results and are sum-
marized together in Figure 2A. Secondary transplants were performed by
injecting 2 3 106 nucleated BM or spleen cells from the primary leukemic
mice into sublethally irradiated (600 rads) B6mice. Histology and immunohis-
tochemical staining details are provided in the Supplemental Experimental
Procedures.
Flow cytometry
Cell suspensions were stained in PBS/2% FBS after blocking with nonspe-
cific rat/mouse IgG (Sigma). Cells were sorted on a MoFlo (Cytomation)
cell sorter. Analytical flow cytometry was performed on a FACS Calibur
(Becton Dickinson) and analyzed using FlowJo software (Treestar). Anti-
bodies used are described in the Supplemental Experimental Procedures.
Dead cells were excluded by a combination of forward and side scatter
properties.
Immunoprecipitation, western blotting, and 35S-methionine
pulse-chase
293T cells were transfected with 3 mg pcDNA3.1/myc-HIS-Trib2 and 2 mg
MigR1-C/EBPa. After 36 hr, cotransfected cells were treated with 10 mM
MG132 for 1 hr and 10 mM N-ethylmaleimide (both Calbiochem) for 30 s,
washed in 13 PBS containing N-ethylmaleimide, and lysed with modified
RIPA buffer (50 mM Tris [pH 8.0], containing 0.5% NP-40, 0.25% sodium de-
oxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na3Vo4, 1 mM
NaF, and 20 mM N-ethylmaleimide) supplemented with protease inhibitors
(Complete EDTA-free; Roche). Precleared lysates (3 mg) were incubated
overnight with 10 ml of protein A beads coated with 5 mg anti-MYC 9E10
antibody. To detect C/EBPa in leukemic samples, cells were lysed directly
in 23 SDS buffer. To detect Flag-tagged Trib2 in leukemic samples, protein
lysates were prepared with modified RIPA buffer. Antibodies used were anti-
C/EBPa (Sc-61, Santa Cruz), anti-HA (HA.11, Covance), anti-FLAG (M2,409
A R T I C L ESigma), and anti-MYC (9E10). In pulse-chase experiments, U937 cells trans-
duced with MigR1 and Trib2 were starved for 30 min, pulse-labeled for
60 min with 35S-methionine (1 mCi/ml), and then chased for up to 180 min.
Precleared protein lysates were incubated overnight with protein G beads
coated with 5 mg C/EBPa antibody (SC-61x). Western blotting was per-
formed according to standard procedures.
Luciferase reporter assay
RAW264.7 macrophages were transfected with various combinations of
pcDNA control vector, vectors encoding Trib2 (390 ng) or C/EBPa (10 ng),
IL-12 p40 (100 ng) wild-type and mutant promoter-luciferase (firefly) con-
structs, and the internal control Renilla-luciferase plasmid pRL-TK (10 ng;
Promega). Firefly and Renilla luciferase activities were measured in whole-
cell lysates using the Dual-Luciferase reporter assay kit (Promega), as per
the manufacturer’s instructions.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSAs) were performed as described
(Keeshan et al., 2003), except that nuclear extracts were prepared using a
Nuclear Extract Kit (Active Motif) as per the manufacturer’s instructions.
The G-CSF receptor promoter oligonucleotide (C/EBP site is underlined)
had the sequence 50-AAGGTGTTGCAATCCCCAGC-30. The Oct-1 consen-
sus oligonucleotide was obtained from Santa Cruz. Two microliters of C/
EBPa (SC-61x) was used for supershift experiments.
Quantitative RT-PCR
RNA, isolated using the RNEasy kit (Qiagen), was digested with DNaseI and
used for reverse transcription according to the manufacturer’s instructions
(Superscript II kit, Invitrogen). Validated human Trib2 and 18s rRNA primer/
probe sets with TaqMan Universal PCR Master Mix (Applied Biosystems)
and murine Trib2 primers (forward, 50-AGCCCGACTGTTCTACCAGA-30; re-
verse, 50-AGCGTCTTCCAAACTCTCCA-30) with SYBR GREEN PCR Master
mix (Applied Biosystems) were used for qRT-PCR and analyzed on the ABI
Prism 7900 sequence detection system (Applied Biosystems).
DNA analysis
Southern blotting was performed according to standard procedures using
QuikHyb (Stratagene) buffer and a 32P-labeled IRES probe.
RNA interference
Human Trib2 siRNA (Silencer Validated siRNA #1060), murine Trib2 siRNA
(Silencer Pre-designed siRNA #169360-exon2), and control Silencer Nega-
tive Control #1 were obtained from Ambion. U937 parental cells (2 3 106)
(expressing human Trib2) and U937 cells that were transduced with Trib2
(murine) in 100 ml of Amaxa solution (Nucleofector Kit V, Amaxa Biosystems)
were mixed with 100 nM of siRNA and electroporated using the Amaxa
Nucleofector. Trib2 (human and murine) mRNA expression and C/EBPa pro-
tein expression were assessed 24 hr later.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
three supplemental figures, and two supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/5/
401/DC1/.
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